To determine the efficacy and safety of Kahook Dual Blade (KDB) goniotomy alone or combined with phacoemulsification cataract surgery to lower intraocular pressure and medication burden in Black and Afro-Latinx patients with open angle glaucoma (OAG). A retrospective, single center case series of patients with OAG who were managed with medications and underwent phacoemulsification combined with goniotomy (PE + KDB) using Kahook Dual Blade or goniotomy alone (KDB alone) in pseudophakic patients. Indications for glaucoma surgery included reduction of intraocular pressure (IOP) and reduction of medication burden. Our study parameters included pre- and postoperative information on IOP, the use of IOP-lowering medications, visual field, and adverse events through 6 months of follow-up. Among all 63 eyes of 63 patients undergoing surgery, Kahook goniotomy with or without phacoemulsification, mean IOP was significantly reduced from 17.4 mmHg at baseline to 14.0 mmHg at month 6 (P = 0.0012), a 19.5% reduction (KDB alone -26.4%, PE + KDB -16.6%). The mean number of topical IOP-lowering medications was reduced from 2.6 at baseline to 1.6 ± 0.3 at month 6 (P = 0.0012), a 38.5% reduction (Kahook alone -10.7%, PE + Kahook -48.0%). Mean visual fields were stable in the PE + KDB group and progressed in the KDB alone group. Postoperative adverse events were mild and included transient hyphema, IOP spikes, posterior capsule opacification, tearing, glare and mild pain. Phacoemulsification combined with Kahook dual blade goniotomy significantly lowers both IOP and medication burden in Black and Afro-Latinx patients with open angle glaucoma. In pseudophakic patients with advanced glaucoma medication burden is not significantly reduced and visual field progression occurred. Adverse events were not sight-threatening and self limited.
1 August 2021 in Journal of the National Medical Association
Currently, IOP reduction is the only way we can help reduce or even stop glaucoma progression. Due to higher rates of blindness in vulnerable poorer groups with decreased access to expensive medications, safer, uncomplicated cataract extraction/refractive lensectomy and microinvasive trabecular bypass surgery should be considered earlier. We need more studies with randomized controlled clinical trials comparing earlier cataract surgery and trabecular bypass to medical, and laser therapies in order to reassess our algorithm for treating enlarged lens-related glaucoma in adults over the age of 50.
Glaucoma is a leading cause of preventable blindness globally. Nearly, half of the patients who have glaucoma in the United States are unaware of their diagnosis, and this number is far greater in resource poor areas. The risk of progressive and irreversible loss of vision is decreased with an early diagnosis, and better access to treatment is vital to improve the visual outcome for patients. We therefore postulated that a minimally invasive, low-cost calculator used to predict the risk of glaucoma and inform the course of follow-up care will improve patient prognosis. We retrospectively examined data from 104 eyes of patients who underwent a complete ocular examination, visual field, and corneal pachymetry at Advanced Eye Care of New York (54 with glaucoma and 50 controls). Receiver operating curves (ROC) were utilized to determine the correct glaucoma classification rates of the Laroche glaucoma calculator (Range −3 to 18), a novel tool that combines age, intraocular pressure (IOP), and central corneal thickness (CCT) into a composite metric. Additionally, we compared the discriminatory power of this calculator to age, intraocular pressure (IOP), and central corneal thickness (CCT) separately. A score of greater than or equal to 6 on the Laroche glaucoma calculator (sensitivity 90.74%, specificity 64.00%, correct classification 77.88%) optimizes the accuracy of this tool. Compared to IOP (Area Under the Curve (AUC) = 0.72, chi2 = 4.21, ) and CCT (AUC = 0.53), chi2 24.72 ), the Laroche glaucoma calculator (AUC = 0.81) was significantly better at discriminating against glaucoma patients vs. controls. These results demonstrate that the Laroche calculator is a novel, effective tool for identifying glaucoma, and it may provide a low-cost risk stratification tool, particularly in areas with limited resources.
1 January 2020 in Therapeutic Advances in Ophthalmology
The purpose was to determine the real-world efficacy of phacoemulsification cataract surgery and Hydrus microstent in Black and Afro-Latinx patients with glaucoma. A retrospective noncomparative single-center study of 76 Black and Afro-Latinx patients with glaucoma who underwent phacoemulsification cataract surgery and Hydrus microstent placement for treatment of glaucoma at single practice. Investigated parameters were intraocular pressure (IOP), number of medications, mean deviation on visual field test, and visual acuity. Patients were also subgrouped into mild, moderate, and advance glaucoma for further analysis. We reviewed a total of 76 patients who had 6 months of follow up in the study. The mean number of medications decreased significantly from 2.6 ± 1.5 preoperatively to 0.72 ± 1.4 in 6 months (p < 0.0010), while IOP decreased from 14.7 ± 3.7 to 13.9 ± 4.3 (p = 0.25). At 6 months, 55 patients (74%) of all patients were medication free (n = 27, 84.4% mild glaucoma; n = 17, 70.8% moderate glaucoma; n = 10, 50% advance glaucoma). There was significant improvement in visual acuity (p < 0.00010) and stabilization of mean deviation on visual field test (baseline −9.2; 6 months −9.1; p = 0.22). The most common adverse effect was a transient IOP spike and transient corneal edema (n = 6, 7.9%; n = 6, 7.9%, respectively) with spontaneous resolution in all cases. No sight-threatening complications were reported at 6 months. This 6-month retrospective study demonstrated the efficacy of phacoemulsification cataract surgery and Hydrus microstent in reducing the medication burden while maintaining lower IOP in Black and Afro-Latinx patients with glaucoma.
1 April 2019 in Journal of the National Medical Association
Glaucoma is a leading cause of preventable blindness, yet nearly half of those affected are unaware of their diagnosis. Individuals with glaucoma may present with “normal” or “lower” intraocular pressure (IOP) compared to typical glaucoma thresholds, due in large part to many of these individuals having thin corneas. Conversely, many with elevated IOP and thicker corneas may not necessarily have glaucoma. In this article, we review the importance of central corneal thickness (CCT) and corneal pachymetry devices in eye care. Additionally, we review the role of corneal thickness as a risk factor for glaucoma and glaucoma progression. PubMed and Web of Science databases were searched for articles and reviews on corneal pachymetry and its use in glaucoma, corneal biomechanics and refractive surgery, and glaucoma screening. The results of this review revealed that CCT is a risk factor for development of glaucoma, and in eyes suspected of glaucoma, corneal pachymetry can be performed by trained technicians to provide important information related to the risk of acquiring glaucoma and/or having other ocular diseases. Additionally, a lower CCT is associated with an increased risk of progression and faster rates of visual field loss in eyes with glaucoma. This review will provide evidence regarding the importance of performing corneal pachymetry on all persons over the age of 50 as part of a comprehensive eye examination to better identify those patients who have glaucoma or are glaucoma suspects. Key Points: CCT has been shown to be a risk factor for the development of glaucoma in eyes suspected of glaucoma.CCT may act as a biomarker for tissues linked to glaucoma, including the lamina cribrosa and peripapillary sclera.A lower CCT is associated with an increased risk of progression and faster rates of visual field loss in eyes with glaucoma.By measuring age, CCT and IOP with the Laroche Glaucoma Calculator, there is a strong relationship for detecting persons at higher risk for glaucoma.Practitioners should consider measuring central corneal thickness in all patients over the age of 50, those at risk for glaucoma, as well as in those already diagnosed with the disease.
About Me
Dr. Daniel Laroche is a glaucoma specialist in New York, Director of Glaucoma Services and President of Advanced Eyecare of New York. Dr. Laroche is a nationally recognized ophthalmologist and the former Chair of the Ophthalmology Section of the National Medical Association.
Dr. Laroche has taken care of thousands of patients from New York and specializes in the diagnosis and treatment of glaucoma.
Dr. Laroche reviewing EMR
Dr. Laroche has performed thousands of glaucoma surgeries using the latest techniques and helped broaden many young surgeons’ understanding of the latest in medical, laser and surgical treatments of glaucoma. Dr. Laroche is an expert in interventional glaucoma including trabeculectomy and glaucoma tube shunt surgery. He is a microincisional glaucoma surgery (MIGS) innovator and instructor and offers patients early cataract surgery and Hydrus Stent and Omni Goniotomy. He is the innovator of the Intrascleral Ciliary Sulcus Suprachoroidal Microtube Technique to lower intraocular pressure in select patients. In a patient with advanced glaucoma, he is the inventor of the Retrobulbar Glaucoma tube shunt technique to lower intraocular pressure without a bleb and reducing the risk of double vision. This vast experience gives Dr. Laroche the unique ability to customize the most appropriate therapies, both medical and surgical, to the glaucoma patients that he serves.
Dr. Daniel Laroche is a glaucoma specialist in New York, Director of Glaucoma Services and President of Advanced Eyecare of New York. Dr. Laroche is a nationally recognized ophthalmologist and the former Chair of the Ophthalmology Section of the National Medical Association.
Dr. Laroche has taken care of thousands of patients from New York and specializes in the diagnosis and treatment of glaucoma.
Dr. Laroche reviewing EMR
Dr. Laroche has performed thousands of glaucoma surgeries using the latest techniques and helped broaden many young surgeons’ understanding of the latest in medical, laser and surgical treatments of glaucoma. Dr. Laroche is an expert in interventional glaucoma including trabeculectomy and glaucoma tube shunt surgery. He is a microincisional glaucoma surgery (MIGS) innovator and instructor and offers patients early cataract surgery and Hydrus Stent and Omni Goniotomy. He is the innovator of the Intrascleral Ciliary Sulcus Suprachoroidal Microtube Technique to lower intraocular pressure in select patients. In a patient with advanced glaucoma, he is the inventor of the Retrobulbar Glaucoma tube shunt technique to lower intraocular pressure without a bleb and reducing the risk of double vision. This vast experience gives Dr. Laroche the unique ability to customize the most appropriate therapies, both medical and surgical, to the glaucoma patients that he serves.